Skip to main content

Table 1 Baseline characteristics of enrolled patients and treatment-emergent adverse event

From: Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial

 

TH, n = 3

TL, n = 3

Placebo, n = 3

TH1

TH2

TH3

TL1

TL2

TL3

C1

C2

C3

Age (years)

47

32

31

32

38

33

39

34

43

Sex

Male

Male

Male

Male

Male

Male

Female

Male

Male

National Early Warning Score 2 (NEWS2)

0

0

0

0

0

1

0

0

1

Co-existing disease

     

Conjunctivitis

Thyroid enlargement

  

Vital signs abnormality

Pre-Hyper-tension

No

Pre-Hyper-tension

Pre-Hyper-tension

Pre-Hyper-tension

Pre-Hyper-tension

Pre-Hyper-tension

Pre-Hyper-tension

Stage 1 Hyper-tension

Chest X-ray abnormality

No

Bilateral hilar lymphadenopathy

Left lobe pneumonia

Right lobe pneumonia

No

No

No

No

Aorta dilatation

Electrocardiography (ECG) abnormality

No

No

No

No

No

No

No

No

No

Laboratory abnormality

       

High level of AST/ALT

 

Treatment emergent adverse event (TEAE)

Right lobe pneumonia

–

Rash maculo-papular

Blood lactate

–

–

Cutaneous candidiasis, myalgia

Hepato-biliary disorder

–

Starting day (duration in days) of TEAE

7*

–

9 (6)

3 (Unknown)

–

–

14 (10; 2)

0 (> 44)

–

  1. TH treatment high-dose group, TL treatment low-dose group, C placebo group
  2. *The first day TEAE was detected following first scheduled chest X-ray (at days 7); the duration was unknown, but no sign of pneumonia was detected following second scheduled chest X-ray examination (at days 14)